Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.54 |
| ▸ | RAB9A | P51151 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KLK7 | P49862 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30134133 | 1.00 | NPC1 (0.54) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL30134094 | 0.84 | SLC2A1 (0.46) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL27293915 | 0.83 | MAPT (0.56) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL6531550 | 0.81 | MAPT (0.54) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL193423 | 0.81 | MAPT (0.59) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL27465286 | 0.81 | MAPT (0.50) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL30390410 | 0.81 | MAPT (0.59) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3388615 | 0.81 | TGFBR1 (0.67) | SMN1; SMN2MAPTMEN1KMT2ATGFBR1 | |
| SCHEMBL31068028 | 0.79 | HPGD (0.53) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| Lithium Ion SCHEMBL31133341 | 0.79 | MAPT (0.57) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115604-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2025-04-10 | — | — | US | disclosed |
| US-12187741-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2025-01-07 | — | — | US | disclosed |
| US-12157734-B2 | Sulfoximine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-12-03 | — | — | US | disclosed |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-08-15 | — | — | US | disclosed |
| EP-3480193-B1 | PYRAZOLE DERIVATIVES AS ALK5 INHIBITORS AND USES THEREOF | HANMI PHARMACEUTICAL CO LTD (KR) | 2024-05-29 | — | — | EP | disclosed |
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024039250-A1 | METHANOGEN INHIBITORS | PASTORAL GREENHOUSE GAS RESEARCH LIMITED (NZ) | 2024-02-22 | — | — | WO | disclosed |
| CN-110770226-B | Sulfoximine glycosidase inhibitors | 阿森纽荣股份公司 | 2023-11-10 | — | — | CN | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | RESVERLOGIX CORP. (CA) | 2009-01-29 | — | — | US | disclosed |
| EP-1909788-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-7297696-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297696-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2007-11-20 | — | — | US | disclosed |
| US-7205316-B2 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1751130-A2 | TRI- AND BI-CYCLIC HETEROARYL HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2007016525-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2007-02-08 | — | — | WO | disclosed |
| US-20050272736-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
| WO-2005113536-A2 | TRI- AND BI-CYCLIC HETEROARYL HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050256309-A1 | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBOTT LABORATORIES | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157734-B2 | Sulfoximine glycosidase inhibitors | ENGASE, BACE1, GAA | NPC1 2614/4885RAB9A 1707/4885ALDH1A1 862/4885 |
| US-20050272736-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | HRH3, HRH4, HRH2 | NPC1 2680/4885RAB9A 924/4885ALDH1A1 3121/4885 |
| US-20250115604-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ENGASE, BACE1, GAA | NPC1 2286/4885RAB9A 1641/4885ALDH1A1 955/4885 |
| US-12187741-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | NPC1 386/4885RAB9A 730/4885ALDH1A1 778/4885 |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | VCAM1, ICAM1, TGFB1 | NPC1 794/4885RAB9A 4410/4885ALDH1A1 893/4885 |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | NPC1 2052/4885RAB9A 981/4885ALDH1A1 1296/4885 |
| US-20050256309-A1 | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands | HRH3, HRH4, HRH2 | NPC1 2680/4885RAB9A 924/4885ALDH1A1 3121/4885 |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | NPC1 2052/4885RAB9A 981/4885ALDH1A1 1296/4885 |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | BACE1, BACE2, BCHE | NPC1 300/4885RAB9A 2306/4885ALDH1A1 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.